Insights and News Library

Stuart Goldblatt Joins CenExel as CEO

Salt Lake City, July 17, 2023 /GlobeNewswire/ — The CenExel Board of Directors is delighted to announce that Stuart Goldblatt has joined CenExel as our new CEO effective July 17, 2023. Tom Wardle will transition to the role of Executive Chairman, CenExel Board of...

Michele Baptista Joins CenExel

Salt Lake City, May 18, 2023 /GlobeNewswire/ — CenExel announces the addition of Michele Baptista as the new Senior Director of Business Development. In this new capacity, Michele will be responsible for developing, selling, and supporting CenExel’s 18-site network...

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

CenExel is proud to announce the publication of the work of Kimball A. Johnson, MD, from CenExel iResearch, in the New England Journal of Medicine. Dr. Johnson participated in a study of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. Other contributors included Evan J. Anderson, MD, C. Buddy Creech, MD, MPH, Vlasimir Berthaud, MD, MPH, Arin Piramzadian, DO, et al., for the KidCOVE Study Froup*

Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

CenExel is proud to announce the publication of the work of Brett English, PharmD, PhD, from CenExel’s Clinical Sciences team, in the Neurogastroenterology & Mortility journal. Dr. English participated in a study of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome. Other contributors included Lin Chang, Brooks D. Cash, Anthony Lembo, David C. Kunkel, Brett English, Beatriz Lindstrom, Guibao Gu, Sharon Skare, Kye Gilder, Stewart Turner, Fabio Cataldi, Donald Lipkis, and Tack Jan. The study aimed to assess the efficacy and safety of olorinab (IBS-D) and constipation (IBS-C).

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.